WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Wednesday, January 17, 2007

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR	
☐	L1	od near 450	533
☐	L2	L1 and lactoferrin	4
☐	L3	hrp$.clm. and 450.clm.	2
☐	L4	horseradish.clm. same peroxidase.clm.	1018
☐	L5	L4 and 450	276
☐	L6	L4 and 450.clm. not l3	4
☐	L7	(horseradish near3 peroxidase) and 450	13847
☐	L8	(horseradish near3 peroxidase) same 450	2007
☐	L9	L8 and elisa.clm.	84
☐	L10	L9 and (fecal or feces or stool or excrement) and (serum or blood or plasma or sera)	16
☐	L11	asca and (panca or p-anca or anca) and lactoferrin	5

END OF SEARCH HISTORY

Cambridge, G., et al., "Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role." Gut, 33: 668-674 (1992).
Das, K.M., et al., "The Production and Characterization of Monoclonal Antibodies to A Human Colonic Antigen Associated with Ulcerative Colitis: Cellular Localization of the Antigen by Using the Monoclonal Antibody." J. Immunology, 139: 77-84 (1987).
Das, K. M., et al., "A Shared and Unique Epitope(s) on Human Colon, Skin, and Biliary Epithelium Detected by a Monoclonal Antibody." Gastroenterology, 98: 464-469 (1990).
Duerr, R. H., et al., "Neutrophil Cytoplasmic Antibodies: A Link Between Primary Sclerosing Cholangitis and Ulcerative Colitis." Gastroenterology, 100: 1385-1391 (1991).
Duerr, R. H., et al., "Anti-Neutrophil Cytoplasmic Antibodies in Ulcerative Colitis. Comparison With Other Colitides/Diarrheal Illnesses." Gastroenterology, 100: 1590-1596 (1991).
Eggena, M., et al., "Characterization of Ulcerative Colitis Specific pANCA Using Phage Display Technology." F. Amer. Society of Exper. Biol., 8(5): A1010 (1994).
Elsaghier, A., et al., "Antibodies to Mycobacterium paratuberculosis-specific protein antigens in Crohn's disease." Clin. Exp. Immunol., 90: 503-508 (1992).
Gross, V. L., et al., "ANCA and associated diseases: immunodiagnostic and pathogenetic aspects." Clin. Exp Immunol., 91: 1-12 (1993).
Halbwachs-Mecarelli, L., et al., "Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis." Clin. exp. Immunol., 90: 79-84 (1992).
Hardarson, S., et al., "Antineutrophil Cytoplasmic Antibody in Inflammatory Bowel and Hepatobiliary Diseases." Am. J. Clin. Pathol., 99: 277-281 (1993).
Kallenberg, C. G. M., et al., "Antineutrophil Cytoplasmic Antibodies: A Still-Growing Class of Autoantibodies in Inflammatory Disorders." Am. J. Med., 93: 675-682 (1992).
King, C. H., et al., "Modulation of Human Neutrophil Effector Functions by Monoclonal Antibodies Against Surface Membrane Molecules of 94,000 and 180,000 Molecular Weight." Blood, 67(1): 188-194 (1986).
Lindberg, E., et al., "Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease." Gut, 33: 909-913 (1992).
Lo, S. K., et al., "Antineutrophil antibody: a test for autoimmune primary sclerosing cholangitis in childhood?" Gut, 34: 199-202 (1993).
Mulder, A. H. L., et al., "Antineutrophil Antibodies in Inflammatory Bowel Disease Recognize Different Antigens." Adv. Exp. Med. Biol., 336: 519-522 (1993).
Mulder, A. H. L., et al., "Prevalence and Characterization of Neutrophil Cytoplasmic Antibodies in Autoimmune Liver Diseases." Hepatology, 17: 411-417 (1993).
O'Mahony, S., et al., "Systemic and mucosal antibodies to klebsiella in patients with ankylosing spondylitis and Crohn's disease." Ann. Rheum. Dis., 51: 1296-1300 (1992).
Rabinovitz, M., et al., "Simultaneous Occurrence of Primary Sclerosing Cholangitis and Autoimmune Chronic Active Hepatitis in a Patient with Ulcerative Colitis." Dig. Dis. Sci., 37(10): 1606-1611 (1992).
Saxon, A., et al., "A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease." J. Allergy Clin. Immunol., 86: 202-210 (1990).
Senecal, J., et al., "Autoantibodies to Major and Minor Nuclear Lamins Are Not Restricted to Autoimmune Diseases." Clin. Immunol. Immunopath., 63(2): 115-125 (1992).
Stevens, T. R., et al., "Anti-Endothelial Cell Antibodies in Inflammatory Bowel Disease." Digestive Dis. and Sci., 38: 426-432 (1993).
Wiesner, R. H., et al., "Clinicopathologic Features of the Syndrome of Primary Sclerosing Cholangitis." Gastroenterology, 79: 200-206 (1980).
Yang, H., et al., "Ulcerative Colitis: A Genetically Heterogeneous Disorder Defined by Genetic (HLA Class II) and Subclinical (Antineutrophil Cytoplasmic Antibodies) Markers." J. Clin. Invest., 92: 1080-1084 (1993).

Peen, E., et al., "Anti-lactoferrin Antibodies and Other Types of ANCA in Ulcerative Colitis, Primary Sclerosing Cholangitis and Crohn's Disease." Gut 34(1): 56-62 (1993).
Bennett, R.M., et al., "Lactoferrin Binds to Neutrophilic Membrane DNA." British Journal of Haematology 63(1): 105-117 (1986).
Jack, R M et al, J. Immunol, vol. 137(12), 1986, pp. 3996-4003.
Lamers, M C et al, Eur. J. Immunol., 1981, vol. 11, pp. 757-764.
Contreras, T J et al, Transfusion, vol. 20 (5) 1980, pp. 519-530.
Rao, K M K, J. Gerontol., vol. 41(5), 1986, pp. 561-566.
Strauss, R G et al, J. Reticuloendothelial Soc., vol. 23(6), Mar. 1978, pp. 177-182.
Matul'skaia, L I et al, Vopr. Med. Khim, Jan.-Feb. 1986, vol. 32(1) pp. 32-34. (Abstract, English).
Briggs (1981) J. Histochem. Cytochem. 29, 1128-1136.
Cohen Tervaert (1992) Gastroenterology 102 (3), 1090.
Zauli (1992) Gastroenterology 102 (3), 1088-1089.
Mulder (1993) Adv. Exp. Med. Biol. 336, 545-549 from Presentation on May 28-30, 1992.

ASCA Seed Gum

DOCUMENT-IDENTIFIER: US 20010036639 A1
TITLE: Method for diagnosing immunologic food sensitivity

CLAIMS:

1. A method for diagnosing an immunologic food sensitivity comprising the steps of: collecting a fecal sample; screening the fecal sample to detect the presence of an antibody to a particular food substance; and diagnosing an immunologic food sensitivity based on the presence of the antibody.

2. The method of claim 1 further comprising the step of concentrating the fecal sample to obtain a testing portion after said collecting step and wherein said testing portion is the sample in said screening step.

4. The method of claim 2 further comprising the step of homogenizing the fecal sample prior to said concentrating step.

8. The method of claim 2 wherein said concentrating step comprises the steps of: centrifuging the fecal sample; removing a supernatant portion from the centrifuged fecal sample; and using the supernatant portion as the testing portion.

12. The method of claim 2 wherein said concentrating step comprises the steps of: freeze-drying the fecal sample to a solid material; and reconstituting the solid material with water to form a reconstituted testing portion.

14. The method of claim 2 wherein said fecal sample contains more than about 90% water in its excreted state and wherein said concentrating step comprises the steps of: freeze-drying the fecal sample to a solid material; and reconstituting the solid material with water to form a reconstituted testing portion.

21. The method of claim 19 wherein said yeast is Saccharomyces cervesiae.

43. The method of claim 33 wherein said sample is a fecal sample.

44. The method of claim 43 further comprising the step of concentrating said fecal sample to obtain a testing portion prior to said screening step and wherein said testing portion is the sample in said screening step.

45. The method of claim 44 further comprising the step of homogenizing the fecal sample prior to concentrating said sample.

49. A method for diagnosing an immunologic drug sensitivity comprising the steps of: collecting a fecal sample; screening the fecal sample to detect the presence of an antibody to a particular drug substance; and diagnosing an immunologic drug sensitivity based on the presence of the antibody.

50. The method of claim 49 further comprising the step of concentrating the fecal sample to obtain a testing portion prior to said screening step and wherein said testing portion is the sample in said screening step.

52. The method of claim 50 wherein said concentrating step comprises the steps of: centrifuging the fecal sample; removing a supernatant portion from the centrifuged fecal sample; and using the supernatant portion as the testing portion.

54. The method of claim 50 wherein said concentrating step comprises the steps of: freeze-drying the fecal sample to a solid material; and reconstituting the solid material with water to form a reconstituted testing portion.

56. The method of claim 55 further comprising the following steps: collecting a fecal sample; screening the fecal sample to detect the presence of an antibody to a particular food substance; and confirming diagnosis of an immunologic food sensitivity based on the presence of the antibody.

57. The method of claim 56 further comprising the step of concentrating the fecal sample to obtain a testing portion and wherein said testing portion is the sample in said screening step.

58. The method of claim 57 further comprising the step of homogenizing the fecal sample prior to concentrating said sample.

60. The method of claim 57 wherein said concentrating step comprises the steps of: centrifuging the fecal sample; removing a supernatant portion from the centrifuged fecal sample; and using the supernatant portion as the testing portion.

62. The method of claim 57 wherein said concentrating step comprises the steps of: freeze-drying the fecal sample to a solid material; and reconstituting the solid material with water to form a reconstituted testing portion.

Previous Doc Next Doc Go to Doc#